Abstract
The ideal dose of the oral anticoagulant warfarin varies widely among patients, mainly due to genetic factors. Genetic variations that impact warfarin pharmacokinetics and the vitamin K cycle are plausible candidates for being associated with warfarin dose requirements. Therefore, the aim of this study was to assess whether polymorphisms in the ABCB1 and CYP4F2 genes were associated with stable warfarin dose requirements in Brazilian patients. This retrospective study included samples from 309 individuals. Genotyping of ABCB1 c.3435C>T and CYP4F2 c.1297G>A were performed by polymerase chain reaction followed by melting curve analysis (HRM-PCR) and TaqMan® genotyping assay, respectively. Stable doses were adjusted in a linear multiple regression model for age, gender, body mass index, self-reported race, use of amiodarone, CYP2C9 (*2 and *3), VKORC1 c.1639G>A, and ABCB1 c.3435C>T or CYP4F2 c.1297G>A. By performing a univariate analysis of variance, we found that the warfarin patients who carry ABCB1 c.3435T variant alleles (CT and TT genotypes) need fewer warfarin stable doses in comparison with the individuals that are CC wild-type: 2.5 (p = 0.003) and 4.3 (p < 0.001) mg/week less, respectively, for the overall group of patients on stable anticoagulation therapeutics (n = 309); and 5.5 (p = 0.006) and 10.2 (p < 0.001) mg/week less, respectively, for the self-declared non-white stable subgroup (n = 76). No statistically significant differences in dose requirements were observed according to CYP4F2 genotypes. In conclusion, our results suggest ABCB1 c.3435C>T variant may influence warfarin dose requirements in Brazilian patients, when associated with other genotypic, demographic and clinical factors.
Highlights
In the last 65 years, warfarin has been the most widely prescribed oral anticoagulant for treating and preventing thromboembolic events (Barnes et al, 2015)
By performing a univariate analysis of variance (ANOVA) for the overall group of patients on stable warfarin treatment (n = 309), we found different mean warfarin doses according to ABCB1 c.3435C>T genotypes p-value (ANOVA) < 0.001; CC: 30.5 ± 0.6 (n = 98), CT: 28.0 ± 0.5 (n = 153), TT: 26.2 ± 0.6 (n = 58)
For the non-white subgroup we found a slight difference in the mean warfarin doses according to CYP4F2 polymorphism: p-value (ANOVA) = 0.048; GG = 29.2 ± 1.1 (n = 47), GA = 33.1 ± 1.0 (n = 27), AA = 33.0 ± 1.9 (n = 2)
Summary
In the last 65 years, warfarin has been the most widely prescribed oral anticoagulant for treating and preventing thromboembolic events (Barnes et al, 2015). The key genetic variants that affect warfarin therapeutic response are presented in the VKORC1 and CYP2C9 genes, which encode the warfarin target enzyme and the primary warfarin metabolizer, respectively (Lee and Klein, 2013). As both these factors can explain 35–50% of the warfarin dose variability (Lee and Klein, 2013), there has been increasing interest in investigating additional clinically important genetic polymorphisms that may further explain interindividual warfarin dose variability among different populations
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
